Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic

Health Economics

Volumn 19, Issue 5, 2010, Pages 518-531

  Lugnér, Anna K ^a   Mylius, Sido D ^a,b   Wallinga, Jacco ^a,c  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b PBL NETHERLANDS ENVIRONMENTAL ASSESSMENT AGENCY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Infectious disease; Modeling choice; Transmission

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; NETHERLANDS; PANDEMIC; PRIORITY JOURNAL; QUALITY OF LIFE; SENSITIVITY ANALYSIS; STATISTICAL MODEL;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DECISION TREES; DISEASE OUTBREAKS; DISEASE TRANSMISSION, INFECTIOUS; HUMANS; INFLUENZA, HUMAN; MODELS, ECONOMETRIC; NETHERLANDS; OSELTAMIVIR;

EID: 77951727815     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1485     Document Type: Article

References (53)

1. Anderson RM, May RM. 1991. Infectious Diseases of Humans: Dynamics and Control. Oxford University Press: Oxford.
2. Anonychuk AM, Tricco AC, Bauch CT, Pham B, Gilca V, Duval B, John-Baptiste A, Woo G, Krahn M. 2008. Cost-effectiveness analyses of hepatitis A vaccine. A systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies. Pharmacoeconomics 26: 17-32.
3. Auld MC. 2003. Choices, beliefs, and infectious disease dynamics. Journal of Health Economics 22: 361-377.
4. Bala MV, Mauskopf JA. 2006. Optimal assignments of treatments to health states using Markov Decision models. An introduction to basic concepts. Pharmacoeconomics 24: 345-354.
5. Baltussen RM, Reinders A, Sprenger MJ, Postma MJ, Jager JC, Ament AJ, Leidl RM. 1998. Estimating influenza-related hospitalization in The Netherlands. Epidemiology and Infections 121: 129-138.
6. Beutels P. 2001. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). Health Economics 10: 751-774. (Pubitemid 34041387)
7. Beutels P, Edmunds WJ, Antonanzas F, De Wit GA, Evans D, Feilden R, Fendrick AM, Ginsberg GM, Glick HA, Mast E, Pechevis M, Van Doorslaer EK, van Hout BA. 2002. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. Pharmacoeconomics 20: 1-7. (Pubitemid 34155211)
8. Brandeau ML, Zaric GS, Richter A. 2003. Resource allocation for control of infectious diseases in multiple independent populations: beyond cost-effectiveness analysis. Journal of Health Economics 22: 575-598. (Pubitemid 36802172)
9. Briggs A, Sculpher M. 1998. An introduction to Markov modeling for economic evaluation. Pharmacoeconomics 13: 397-409. (Pubitemid 28140699)
10. Brennan A, Chick SE, Davies R. 2006. A taxonomy of model structures for economic evaluation of health technologies. Health Economics 15: 1295-1310. (Pubitemid 44941606)
11. Brisson M, Edmunds WJ. 2003. Economic evaluation of vaccination programs: the impact of herd-immunity. Medical Decision Making 23: 76-82. (Pubitemid 36133362)
12. Brisson M, Edmunds WJ. 2006. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Medical Decision Making 26: 434-446. (Pubitemid 44410295)
13. Brouwer WBF, Koopmanschap MA. 2005. The friction-cost method. Replacement for nothing and leisure for free? Pharmacoeconomics 23: 105-111.
14. CBS, Statistics Netherlands. Database, Statistical Informatics Department of Statistics Netherlands, Voorburg, the Netherlands. URL http://statline.cbs. nl/. (Accessed on 1 December 2006).
15. CVZ. 2006. Guidelines for Pharmacoeconomic Research, Updated Version. Valid from April 1st 2006, Diemen.
16. Drummond M, Chevat C, Lothgren M. 2007. Do we fully understand the economic value of vaccines? Vaccine 25: 5945-5957.
17. Duintjer Tebbens RJ, Thompson KM, Hunink MG, Mazzuchi TA, Lewandowski D, Kurowicka D, Cooke RM. 2008. Uncertainty and sensitivity analyses of a dynamic economic evaluation model for vaccination programs. Medical Decision Making 28: 182-200. (Pubitemid 351441943)
18. Edmunds WJ, Medley GF, Nokes DJ. 1999. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Statistics in Medicine 18: 3263-3282.
19. Ferguson N. 2006. Poverty, death, and a future influenza pandemic. Lancet 368(9554): 2187-2188. (Pubitemid 44958996)
20. Ferguson NM, Cummings DAT, Cauchemez S, Fraser C, Riley S, Meeyai A, Iamsirithaworn S, Burke DS. 2005. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 437: 209-214. (Pubitemid 41294478)
21. Fukuda K, Levandowski RA, Bridges CB, Cox NJ. 2004. Inactivated influenza vaccines. In Plotkin SA, Orenstein WA (eds). Vaccines. Saunders: Philadelphia.
22. Geoffard PY, Philipson T. 1997. Disease eradication: private versus public vaccination. The American Economic Journal 87: 222-230. (Pubitemid 127454257)
23. Germann TC, Kadau K, Longini Jr IM, Macken CA. 2006. Mitigation strategies for pandemic influenza in the United States. Proceedings of the National Academy of Science of the USA 103: 5935-5940.
24. Health Council of the Netherlands. 2005. Gezondheidsraad. Gebruik van antivirale middelen en andere maatregelen bij een grieppandemie. Gezondheidsraad: Den Haag (In Dutch) Publication nr 2005/05.
25. Hirotsu N, Ikematsu H, Iwaki N, Kawai N, Shigematsu T, Kunishima O et al. 2004. Effects of antiviral drugs on viral detection in influenza patients and on the sequential infection to their family members - serial examination by rapid diagnosis (Capilia) and virus culture. In Kawaoka Y (ed.). Options for Control of Influenza, vol. V. Elsevier Science Publishers: Amsterdam.
26. Jordan Jr WS, Denny Jr FW, Badger GF, Curtiss C, Dingle JH, Oseasohn R, Stevens DA. 1958. A study of illness in a group of Cleveland families. XVII. The occurrence of Asian influenza. American Journal of Hygiene 68(2): 190-212.
27. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. 2003. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Archive of Internal Medicine 163: 1667-1671. (Pubitemid 36898954)
28. Keeling MJ, Rohani P. 2008. Modeling Infectious Diseases in Humans and Animals. Princeton University Press: Princeton, Oxford.
29. Kim SY, Goldie SJ. 2008. Cost-effectiveness analyses of vaccination programmes. A focused review of modeling approaches. Pharmacoeconomics 26: 191-215.
30. Koopmanschap MA, Rutten FFH, van Ineveld BM, van Roijen L. 1995. The friction cost method for measuring indirect costs of disease. Journal of Health Economics 14: 171-189.
31. Longini Jr IM, Nizam A, Xu S, Ungchusak K, Hanshaoworakul W, Cummings DAT, Halloran ME. 2005. Containing pandemic influenza at the source. Science 309: 1083-1087.
32. Lipsitch M, Cohen T, Murray M, Levin BR. 2007. Antiviral resistance and the control of pandemic influenza. PloS Medicine 4: e15. (Pubitemid 46191826)
33. Lynd LD, Goeree R, O'Brien BJ. 2005. Antiviral agents for influenza. A comparison of cost-effectiveness data. Pharmacoeconomics 23: 1083-1106.
34. Miller MA, Redd S, Hadler S, Hinman A. 1998. A model to estimate the potential economic benefits of measles eradication for the United States. Vaccine 16: 1917-1922. (Pubitemid 28473935)
35. Mylius SD, Hagenaars TJ, Lugnér AK, Wallinga J. 2008. Optimal allocation of pandemic influenza vaccine depends on age, risk and timing. Vaccine 26: 3742-3749.
36. Mäkelä MJ, Pauksens K, Rostila T, Fleming DM, Man CY, Keene ON, Webster A. 2000. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. Journal of Infection 40: 42-48. (Pubitemid 30157772)
37. Newall AT, Beutels P, Wood JG, Edmunds WJ, MacIntyre CR. 2007. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infectious Diseases 7: 289-296. (Pubitemid 46414076)
38. Nguyen-Van-Tam JS, Hampson AW. 2003. The epidemiology and clinical impact of pandemic influenza. Vaccine 21: 1762-1768.
39. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH. 2004. Handleiding voor kostenonderzoek, methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. geactualiseerde versie 2004. College Voor Zorgverzekeringen: Diemen (In Dutch).
40. Pisu M, Meltzer MI, Hurwitz ES, Haber M. 2005. Household-based costs and benefits of vaccinating healthy children in daycare against influenza virus. Results from a pilot study. Pharmacoeconomics 23: 55-67.
41. Postma MJ, Jansema P, Scheijbeler HWKFH, van Genugten MLL. 2005. Scenarios on costs and savings of influenza treatment and prevention for Dutch healthy working adults. Vaccine 23: 5365-5371. (Pubitemid 41579307)
42. Pradas-Velasco R, Antoñanzas-Villar F, Martínez- Zárate MP. 2008. Dynamic modeling of infectious diseases. An application to the economic evaluation for influenza vaccination. Pharmacoeconomics 26: 45-56.
43. Rothermich EA, Pathak DS. 1999. Productivity-cost controversies in cost-effectiveness analysis: review and research agenda. Clinical Therapeutics 21: 255-267.
44. Sadique MZ, Edmunds WJ, Smith RD, Meerding WJ, de Zwart O, Brug J, Beutels P. 2007. Precautionary behavior in response to perceived threat of pandemic influenza. Emerging Infectious Diseases 13: 1307-1313. (Pubitemid 47510291)
45. Sonnenberg FA, Beck JR. 1993. Markov models in medical decision making: a practical guide. Medical Decision Making 13: 322-338.
46. Sprenger MJW, Mulder PGH, Beyer WEP, van Strik R, Masurel N. 1993. Impact of influenza on mortality in relation to age and underlying disease, 1967-1989. International Journal of Epidemiology 22: 334-340. (Pubitemid 23129339)
47. Stiver G. 2003. The treatment of influenza with antiviral drugs. Canadian Medical Association Journal 168: 49-57.
48. Van Genugten MLL, Heijnen M-LA, Jager JC. 2003. Pandemic influenza and healthcare demand in the Netherlands: scenario analysis. Emerging Infectious Diseases 9: 531-538.
49. Wallinga J, Lipsitch M. 2007. How generation intervals shape the relationship between growth rates and reproductive numbers. Proceedings of the Royal Society of London B 274: 599-604. (Pubitemid 47055535)
50. Wallinga J, Teunis P, Kretzschmar M. 2006. Using data on social contacts to estimate age-specific transmission parameters for respiratory-spread infectious agents. American Journal of Epidemiology 164: 936-944. (Pubitemid 44729833)
51. Wearing HJ, Rohani P, Keeling MJ. 2005. Appropriate models for the management of infectious diseases. PloS Medicine 2: e174. (Pubitemid 46179273)
52. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR. 2003. Principles of good clinical practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on good research practices-modeling studies. Value in Health 6: 9-17. (Pubitemid 36228345)
53. Welte R, Postma M, Leidl R, Kretzschmar M. 2005. Costs and effects of Chlamydial screening: dynamic versus static modeling. Sexually Transmitted Diseases 32: 474-483. (Pubitemid 41060386)